Special Issue "The Interplay of Gut Dysbiosis with Metabolic Syndrome"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Microbiology in Human Health and Disease".

Deadline for manuscript submissions: 31 January 2024 | Viewed by 1581

Special Issue Editor

New York Medical Research Scientist, New York Medical College, New York, NY, USA
Interests: metabolic syndrome; high blood pressure and abnormal cholesterol levels; diabetes and insulin resistance; cardiovascular diseases; kidney damage and fibrosis; nano-medicine and toxicology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Dysbiosis of the gut microbiota plays a crucial role in the pathogenesis of metabolic syndrome, both in human and animal models. Diet has a significant impact on both the microbial composition of the gut and its activities. This multi-component intestinal “superorganism” is thought to influence the metabolic equilibrium of the host. It controls how much energy is taken in, how fast the gut moves, how hungry the host is, how much glucose the host has in its blood, how the host liver uses fat, and how much fat the liver stores. Overgrowth of one species of microbes causes dysbiosis, and disturbed gut homeostasis is called dysbiosis. Disruption in the delicate equilibrium that exists between the microbes in the gut and the immune system of the host could ultimately result in the intestinal translocation of bacterial fragments and the development of "metabolic endotoxemia," which would then cause inflammation throughout the body as well as insulin resistance. This Special Issue will shed light on dysbiosis and its connections to ‘metabolic syndrome.” Dysbiosis causes a cluster of interrelated physiological, biochemical, clinical, and metabolic risk factors that are associated with an increased likelihood of developing cardiovascular disease and type 2 diabetes. The main characteristics of metabolic syndrome are elevated blood pressure, dyslipidemia (defined as increased triglycerides and reduced high-density lipoprotein cholesterol), elevated fasting glucose, and central obesity. Manipulation of gut microbiota through the administration of prebiotics or probiotics could reduce intestinal low-grade inflammation and improve gut barrier integrity, thereby improving metabolic balance and promoting weight loss. However, additional evidence is required to fully comprehend their clinical impact and the therapeutic application of dysbiosis and its link with metabolic syndrome.

We invite researchers working on the effects of gut dysbiosis on metabolic syndrome to submit original research articles or review papers for this Special Issue in order to advance our understanding of this complicated and intriguing topic. The following are examples of possible topics; however, this list is not exhaustive.

A cluster of interconnected physiological, biochemical, clinical, and metabolic risk factors are caused by gut dysbiosis. These risk factors are associated with an increased chance of developing cardiovascular disease and type 2 diabetes.

It is possible that strengthening the integrity of the gut barrier and reducing low-grade inflammation in the intestines might be accomplished through manipulation of the gut microbiota using prebiotics and probiotics. This would result in improved metabolic balance and the facilitation of weight reduction.
However, therapeutic approaches are necessary for the clinical symptoms of dysbiosis, and for the therapy and treatment of metabolic syndrome.

Dr. Shailendra Pratap Singh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • gut microbiota dysbiosis
  • metabolic syndrome
  • pathogenesis
  • immune system
  • cardiovascular diseases
  • prediabetes

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


14 pages, 9520 KiB  
Ruminococcaceae_UCG-013 Promotes Obesity Resistance in Mice
Biomedicines 2022, 10(12), 3272; https://doi.org/10.3390/biomedicines10123272 - 16 Dec 2022
Cited by 5 | Viewed by 1307
Alterations in the gut microbiome have been linked to obesity and type 2 diabetes, in epidemiologic studies and studies of fecal transfer effects in germ-free mice. Here, we aimed to identify the effects of specific gut microbes on the phenotype of mice fed [...] Read more.
Alterations in the gut microbiome have been linked to obesity and type 2 diabetes, in epidemiologic studies and studies of fecal transfer effects in germ-free mice. Here, we aimed to identify the effects of specific gut microbes on the phenotype of mice fed a high-fat diet (HFD). After eight weeks of HFD feeding, male C57BL/6J mice in the HFD group ranking in the upper and lower quartiles for body weight gain were considered obese prone and obese resistant, respectively. 16S rRNA gene sequencing was used to determine the composition of the intestinal microbiota, and fecal transplantation (FMT) was conducted to determine whether the microbiota plays a causal role in phenotypic variation. Ruminococcaceae_UCG-013 was more abundant in the gut microbes of mice with a lean phenotype than in those with an obese phenotype. Ruminococcaceae_UCG-013 was identified as the most significant biomarker for alleviating obesity by random forest analysis. In a correlation analysis of serum parameters and body weight, Ruminococcaceae_UCG-013 was positively associated with serum HDL-C levels and negatively associated with serum TC, TG, and LDL-C levels. To conclude, Ruminococcaceae_UCG-013 was identified as a novel microbiome biomarker for obesity resistance, which may serve as a basis for understanding the critical gut microbes responsible for obesity resistance. Ruminococcaceae_UCG-013 may serve as a target for microbiome-based diagnoses and treatments in the future. Full article
(This article belongs to the Special Issue The Interplay of Gut Dysbiosis with Metabolic Syndrome)
Show Figures

Figure 1

Back to TopTop